ACADIA Pharmaceuticals Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ACADIA Pharmaceuticals Inc.
BIO CEO panelist Rajeev Venkayya argued that the huge amount of investment in COVID-19 vaccines makes it possible for new players to challenge Comirnaty and Spikevax’s dominance.
Pharmaceutical quality leadership proposes eight-step “dance” with complex global regulatory system for allowing manufacturing processes to improve more quickly. The data showed many authorities take more than the recommended six months to decide on post-approval changes, with assessments taking almost eight years in some cases.
An analyst is calling data from Viking’s Phase II study of GLP-1/GIP agonist VK2735 best-in-class, even compared with approved therapies, with 13-week weight reductions as high as 14.7%.
The gene therapy company could have two products approved by the end of 2024 – with ambitions for long-term expansion beyond rare disease.
- Other Names / Subsidiaries
- Receptor Technologies
- CerSci Therapeutics
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.